Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 38.7% in November

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 4,300 shares, a growth of 38.7% from the October 31st total of 3,100 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is presently 0.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Trading Up 0.9 %

NASDAQ:ANL traded up $0.02 during trading hours on Friday, hitting $2.23. The company’s stock had a trading volume of 1,954 shares, compared to its average volume of 11,709. Adlai Nortye has a 52-week low of $1.85 and a 52-week high of $17.48. The business’s 50-day moving average is $2.27 and its two-hundred day moving average is $3.76.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.